hims & hers fda warning letter compounded semaglutide 2025 May Discontinue Weight-Loss Drugs Following Decision The FDA sent a warning

We also know it extends beyond excruciating pain, to light sensitivity and nausea

NICE guidelines (NG28) recommend GLP-1 agonists as second- or third-line therapy for type 2 diabetes when metformin and other agents are insufficient or unsuitable

Importantly, because Dihexa promotes true structural changes in synaptic connections rather than temporary stimulation, improvements often persist beyond treatment cessation

Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study

Phase III randomized, placebo-controlled trial of endocrine therapy 1 year of everolimus in patients with high-risk, hormone receptor-positive, early-stage breast cancer